Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q1 FY25 Earnings Presentation
22 slides from Balaxi Pharmaceuticals's earnings presentation, Aug 5, 2024
Slide 1: NSE filing cover letter: Investor Presentation
August 05, 2024 To, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30 of SEBI (Listing Obligations and
Slide 2: Balaxi Pharmaceuticals Limited Investor Presentation
Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Forward-looking statements disclaimer
Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to
Slide 4: Corporate Snapshot, Financial Highlights, Strategic Roadmap
04 Corporate Snapshot 14 Financial Highlights 20 Strategic Roadmap Balaxi
Slide 5: Balaxi company overview
M= Branded IPR-based pharma = company Frontier markets leadership in Latin America and Africa Vast portfolio across diverse therapeutic areas Asset light structure for expansion in semi-regulated markets Balaxi
Slide 6: Supply Chain and Distribution
Expansion initiated: Nicaragua, Ecuador, Chile (Latin America) 989 product registrations in eight countries 700+ registrations submitted or in the pipeline Establishing the Company’s first Supply Chain pharmaceutical formulation facility in Hyderabad Successful process being replicated in other Dist
Slide 7: Key Success Factors
Key Success Factors Market Selection Methodology = Focus on countries with high-potential economic growth framework = |dentify non-English speaking countries with similar characteristics = Low competitive intensity and potential to establish top-2 position = On-ground feedback mechanism allows deep
Slide 8: Transition from Asset Light to Asset Right
Transition from “Asset Light” to “Asset Right” Marketing and Market Research ’ Product Product Manufacturing ’ Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from ‘Asset Light’ to Asset Rig
Slide 9: Investment in Manufacturing Facilities
' Investment in Manufacturing Facilities Lo ° N . L] L] L] . ° . L] Setting up its first pharmaceutical formulation manufacturing unit ° General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain
Slide 10: Global Footprint
Global Footprint China Existing Market Dominican chins . 5 Republic . Targeted Expansion Guatemala Honduras El Salvador @ Product Sourcing Regions African Republic Ecuador e . Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of S 6 billion
Slide 11: Key Milestones
Key Milestones o Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers
Slide 12: Corporate Structure
Corporate Structure laxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) 1 1 v Balaxi Balaxi Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Central African SRL (WOS) S.A (WOS) (WOs) (WOS) Republic(WOS) Balaxi Health
Slide 13: Board of Directors
Ashish Maheshwari Minoshi Maheshwari Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Balaxi experience, manages First Water qu
Slide 14: Dynamic Leadership Team
Dynamic Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associat
Slide 15: Financial Highlights
FINANCIAL HIGHLIGHTS 0 4 A A\ A Balaxi
Slide 16: Management's Comments
Management’s Comments “In Q1 FY25, despite the tough operating environment marked by geo-political upheavals, inflationary trend, currency fluctuations and supply chain issues, we have strategically focused on our geographies in Latin American markets, and also successfully sailed through the challe
Slide 17: Quarterly Financial Performance
“Quarterly Financial Performance Particulars (InR crore) Q1 FY24 Revenue 65.95 25.64 Gross Margin % 38.9% EBITDA before exceptional item™ 8.84 EBITDA Margin % before exceptional item™ 13.4% Profit After Tax* (41.34) PAT Margin %* (62.7%) Exceptional It (46.67) *Exceptional Item pertaining to Q1 FY23
Slide 18: Pharma Product Mix — Q1 FY25
Pharma Product Mix— Q1 FY25 Geographies Products m Africa* = Branded u LATM** = Generics Dosage Forms Therapeutic Areas m Tablets m Antibiotics 38% = |njectables = Analgesic = Liquids = Anti-malaria = Capsules = Others m Others 18% Ba’ax’ *Africa: Angola and Central African Republic *LATM - Guatemal
Slide 19: Financial performance (INR crore)
Particulars (INR crore) . Revenue Gross Margin 2 ITDA EBITDA Margin Profit After Tax PAT Margin % Earnings Per Share (INR) *NOTE: During the 1t quarter of the year, the Angolan currency Kwanza underwent an unprecedented sharp depreciation, falling from 511.50 AOA/USD to 832.5 AOA/USD. Since the cred
Slide 20: Pharma Product Mix — FY24
Pharma Product Mix— FY24 Geographies Products m Africa* = Branded u LATAM** = Generics Dosage Forms Therapeutic Areas m Tablets m Antibiotics = Injectables 46% ) = Analgesic = Liquids = Anti-malaria vg = Capsules = Others m Others 6% Ba’ax’ *Africa: Angola and Central African Republic *LATAM — Guate
Slide 21: Core Strategy: Enter, Expand & Excel
' Core Strategy: Enter, Expand & Excel s Balaxi in 2020: Business Consolidation .. = Presence across Angola, Guatemala and Dominican Republic = Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-24: Expansion into New Geographies = Aim
Slide 22: Thank You / Contact
Our Offerings Balaxi Pharmaceuticals Limited Others Anti-Emetic Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 @ Sunny Purohit © +91-40-2355-5300 B4 sunny@balaxi.com @® www.balaxipharma.in ® NSE BALAXI Bloomberg BALAXI:IN
Balaxi Pharmaceuticals — Q1 FY25 Earnings Presentation on 6ix